ICON has conducted diabetes trials in all global regions and has particular experience in running studies in emerging regions such as Eastern Europe, India and South America where there are large pools of Type I and Type II diabetes patients. ICON has a network of offices in these regions and has developed strong relationships with investigator sites to ensure high rates of patient enrolment and retention.
Glucose clamping techniques offer more adaptable and reproducible procedures than ever before in the development of new agents to treat Type 1 and Type 2 diabetes. Clients using ICON’s Glucose Clamping services are getting key proof of concept data 90% faster and at lower cost.
To overcome the unique challenges of clinical development in metabolic disorders, ICON has created a team of in-house global experts to support and oversee drug development programmes. The TAG members share a common expertise in metabolic disorders in their areas of competence; medical, laboratory, imaging operations, statistics and consulting. They provide therapeutic indication training to the project team to enable studies to get up and running soon and to meet aggressive project timelines. TAG members are a permanent resource for the study team throughout the course of the project.
ICON is supporting the use of mobile and wearable technologies to help people with diabetes to better manage their condition. In September 2015, ICON sponsored cyclists in the mHealth Grand Tour which delivered a world-first solution to track blood glucose levels and other key vital diabetes statistics online and in real-time. Equipped with a range of wearables which were supported by mobile technologies, the tour also gave patients new insights and information on how their condition evolved during the day.